High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) are established components in the treatment of multiple myeloma; however, undergoing transplantation usually requires hematopoietic support, which poses a challenge among patients who are unwilling to receive blood products. Most transplant centers decline HDT/ASCT to these patients because of safety concerns. Here, the authors' institutional data on safety, engraftment parameters, and survival outcomes after bloodless ASCT (BL-ASCT) are examined among patients with myeloma. This retrospective case-control study included patients who underwent BL-ASCT and Transfusion-supported ASCT (TS-ASCT) at Emory University Hospital between August 2006 and August 2016. In total, 24 patients who underwent BL-ASCT and 70 who underwent TS-ASCT were included. The median time for neutrophil engraftment, platelet engraftment and the median length of hospital stay all were equivalent for both groups. There were no transplant-related cardiovascular complications or mortality in either the BL-ASCT group or the TS-ASCT group. The median progression-free survival was 36 months and 44 months in the BL-ASCT and TS-ASCT groups, respectively (P = .277), and the median OS was not reached in either group at a median follow-up of 59 months after ASCT (P = .627). There was no transplant-related mortality at the 100-day or 1-year mark in either group. BL-ASCT is safe and feasible; transplant-related mortality, cardiovascular and hematologic complications are similar to those associated with TS-ASCT. Furthermore, BL-ASCT can yield similar engraftment and survival parameters comparable to those observed with TS-ASCT. Cancer 2019;125:185-193.
INTRODUCTION
The use of combined high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) with novel combinations of plasma cell-directed agents earlier in the disease course has resulted in improved progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma. Although most phase 3 studies demonstrate the benefit of HDT-ASCT over a nontransplant approach, most transplant centers do not offer HDT-ASCT to patients who decline blood products because of safety concerns associated with a presumption of increased cardiovascular (CV) and bleeding complications and thus higher transplant-related mortality (TRM). The myeloablative dose of melphalan used before stem cell infusion suppresses hematopoiesis, and supportive transfusions of erythrocytes and platelets typically are used until engraftment to minimize bleeding complications and the clinical sequelae of anemia. Previous studies among patients who were Jehovah's Witnesses (JWs), a denomination that does not accept blood products for religious reasons, reported the feasibility of HDT-ASCT among JW patients, but the CV risks, bleeding risks, and TRM were higher than what is generally acceptable for patients with myeloma who undergo HDT-ASCT. 1 Using a specified protocol aimed at supporting patients' hematologic requirements without transfusions, we have demonstrated the safety of bloodless ASCTs (BL-ASCTs) that produce minimal CV and bleeding complications and importantly, no increased TRM. Of the 1680 HDT-ASCTs performed for patients with myeloma at the Winship Cancer Institute of Emory University over the last decade, we present our institutional experience, along with safety and engraftment parameters of 24 BL-ASCTs performed for patients with myeloma.
METHODS

Study Design and Participants
We assessed 24 consecutive BL-ASCT procedures received by patients who had newly diagnosed, symptomatic myeloma, most of whom had received novel agent-based induction regimens and underwent stem cell harvest at the Emory Cancer January 15, 2019
University Winship Cancer Institute between August 2006 and August 2016. According to our institutional practice, patients who received induction therapy and achieved at least a partial response then underwent stem cell mobilization and had adequate stem cells harvested for at least 1 transplant according to the International Myeloma Working Group (IMWG) criteria. Institutional Review Board approval was obtained to perform this outcome analysis evaluating the safety of BL-ASCT. We also performed a matched-pair, comparative analysis of outcomes in the BL-ASCT cohort with the outcomes of patients who underwent transfusion-supported ASCT (TS-ASCT) on a 1:3 accrual basis. For each patient who underwent BL-ASCT, 3 patients who underwent TS-ASCT during the same period, matched by age (±5 years), sex, race and risk status, were identified from our myeloma database. Only 2 controls who matched the criteria were available for 1 patient who had light-chain amyloidosis (AL amyloidosis) and for 1 younger patient with myeloma. Pertinent data were obtained from our institutional myeloma database, which captures all patient data and is continuously updated with periodic quality checks. The data cutoff was August 31, 2017. Patient characteristics are summarized in Table 1 .
Patients who met our criteria underwent stem cell collection using granulocyte-colony-stimulating factor (G-CSF) mobilization, and standard apheresis techniques were used. According to our institutional practice, transplantation-eligible patients had adequate cardiac and pulmonary reserve without any known active viral or bacterial infections. A decision to pursue BL-ASCT was made at the discretion of the physician based on patient preference at the time of the initial consultation. All pertinent plasma disorder staging and restaging laboratory values at the time of diagnosis and at stem cell harvest were assessed in each patient. The standard pretransplantation conditioning regimen was melphalan 200 mg/m 2 , except for patients with renal failure and/or older patients (defined as age >70 years) with a poor performance status, who received melphalan 140 mg/m 2 . Patients received an infusion of stem cells on day 0, and there was no difference in target stem cell collection or infusion for the BL-ASCT group. Cryotherapy before and during melphalan administration was encouraged in all patients to prevent mucositis. In addition, all patients received palifermin, a keratinocyte growth factor, as well as infectious prophylaxis with an antibacterial (levofloxacin), an antiviral (acyclovir), and an antifungal (fluconazole) agent until engraftment. Patients received G-CSF subcutaneously daily starting on day 7 after ASCT until they attained neutrophil engraftment, which was defined as an absolute neutrophil count ≥0.5 × 10 9 /L on 3 consecutive days.
Our institutionally developed protocol for BL-ASCT was used for all patients. A goal of hemoglobin >11 g/dL was attained before patients were admitted for transplantation, and blood loss was minimized using pediatric tubes and by limiting laboratory draws to twice weekly. Additional supportive measures (using aminocaproic acid, erythropoietin-stimulating agents, iron supplementation, proton pump inhibitors, suppression of menses in women at risk, etc) also were incorporated into patient care (Tables 2 and 3) .
Statistical Analysis
All patients who undergo ASCT are evaluated after day 30 and after day 100 with restaging laboratory evaluations. At the restaging discussion with the patient on or after day 100, maintenance therapies for gaining prolonged disease control were offered. Responses were assessed using the IMWG uniform response criteria. PFS was calculated as time from ASCT to disease progression or mortality from any cause. OS was defined as the time from diagnosis to the date of death or last follow-up. Chi-square and Fisher exact tests were used to compare differences between categorical variables, and the nonparametric Mann-Whitney test was used for continuous variables. Survival projections of PFS and OS were estimated using the Kaplan-Meier method and were compared using log-rank tests. The SPSS software package (version 24; SPSS, Inc, Chicago, IL) was used for analysis.
RESULTS
Patient Characteristics
From August 2006 to August 2016, 24 patients with plasma cell dyscrasias (myeloma, n = 23; AL amyloidosis, n = 1) who underwent BL-ASCT were included in the analysis. A contemporaneous cohort of 70 patients (myeloma, n = 68; AL amyloidosis, n = 2) who underwent TS-ASCT and were matched by age, sex, race, and risk status was used as a control group to compare safety outcomes, engraftment parameters, and survival outcomes. Patient characteristics are summarized in Table 1 . The median patient age at the time of diagnosis and transplantation was 55 years (range, 33-70 years) and 56 years (range, 37-71 years), respectively for patients in the BL-ASCT group, and 53.5 years (range, 26 to 66 years) and 53.5 years (range, 27 to 68 years), respectively, for those in the TS-ASCT group. The BL-ASCT and TS-ASCT groups were well matched, and no statistically Cancer January 15, 2019 significant differences were observed between the 2 groups. Approximately, two-thirds of the patients were black, and 60% were women. Approximately 20% of patients in both groups were considered high-risk, as anticipated, based on their initial presentation with plasma cell leukemia or abnormal myeloma fluorescence in situ hybridization (FISH) or cytogenetic profiles of del17p deletion and t(4:14) or t(14;16) translocation. Table 4 summarizes the clinical laboratory values at presentation, which were comparable between the 2 groups. The median hemoglobin level at the time of diagnosis in the BL-ASCT group and the TS-ASCT group was 11 g/dL (range, 7.5-14.1 g/dL) and 10.55 g/dL (6.9-15.1 g/dL; P = .377), respectively. Similarly, platelet counts at the time of diagnosis were similar across both groups (BL-ASCT, 228,000/μL [94,000-506,000/μL]; TS-ASCT, 229,500/μL [70,000-515,000/μL]; P = .939). More than 90% of patients in both groups received a novel agentbased induction regimen prior to transplant, and most received triplet regimens (bortezomib, lenalidomide, and dexamethasone; bortezomib, thalidomide, and dexa methasone; or carfilzomib, lenalidomide, and 
TABLE 2. Bloodless Autologous Stem Cell Transplantation Objectives
Methods to minimize blood loss include, but are not limited to:
• Achieving a target Hgb >11 g/dL at the time of admission for transplantation • Minimizing blood loss using phlebotomy with a closed system for blood samples (eg, using the "push-pull" method to maintain continuity) AND minimizing laboratory draws to those only deemed medically necessary by the attending physician (eg, twice weekly) • Use of supportive care agents (for further details, see Table 3 ), including aminocaproic acid, ESAs with iron supplementation, desmopressin, oxygen, and IV fluids for volume support and to alleviate the need for blood products • Adherence to a diet rich in iron • Suppression of menses in women at risk Abbreviations: ESAs, erythropoietin-stimulating agents; Hgb, hemoglobin.
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Pre-ASCT Clinical Characteristics
The BL-ASCT protocol was discussed with patients at the time of ASCT consultation and consent. The median hemoglobin level before transplantation in the BL-ASCT and TS-ASCT groups was 10.7 g/dL (range, 8.8-13.6 g/dL) and 10.5 g/dL (range, 6.8-12.90 g/dL), respectively (P = .91). Achieving a target hemoglobin level of 11 g/dL before admission for ASCT was attempted using erythropoietin stimulating agents and iron supplementation, as outlined in the BL-ASCT protocol (Table 3 ), but this threshold was not required to proceed to transplantation. Because a majority of patients in the BL-ASCT group came from out of state, the referring oncologist also was provided with a copy of the BL-ASCT protocol and encouraged to follow it locally. While the graft was mobilized, patients were given a 4-week to 6-week period of recovery after completing induction therapy and before their admission for BL-ASCT, during which time, the BL-ASCT protocol was encouraged. This also helped with the normalization of other hematologic parameters and provided ample time for bone marrow recovery from the myelosuppressive agents used in the induction therapy. Platelet counts pre-transplant in the BL-ASCT and TS-ASCT groups were similar: 222,000/μL (range, 570,00-366,000/μL) and 221,000/μL (range, 35,000-511,000/μL) respectively (P = .91). Baseline cardiac and pulmonary function was evaluated according to institutional practice in all patients. The median ejection fraction for the BL-ASCT and TS-ASCT groups were 60% (range, 45%-75%) and 60% (range, 30%-79%), respectively (P = .968); and the median diffusing capacity of the lung for carbon monoxide was 78.50% (range, 53%-118%) and 74% (range, 36%-107%), respectively (P = .426) ( Table 5 ).
Engraftment Parameters
Engraftment data for both groups are summarized in Table 6 . The median time to neutrophil engraftment for the BL-ASCT group was 12 days (range, 11-17 days), which was equivalent to that for the TS-ASCT group (12 days; range, 10-17 days; P = .929). The median time to platelet engraftment also was similar in both groups (BL-ASCT vs TS-ASCT: 13.5 days [range, 11-27 days] vs 14 days [range, 7-34 days]; P = .482). The median length of stay was equivalent for both groups (BL-ASCT vs TS-ASCT: 15.5 days [range, 12-24 days] vs 16 days [range, 12-29 days]; P = .737).
Transfusion Requirements
All patients signed a consent form for receipt or refusal of blood products before ASCT. According to institutional guidelines, transfusions of packed red blood cells (PRBCs) and platelets are routinely administered in the hospital setting for patients who have hematocrit values <25% and platelet counts <10,000/μL. Although no PRBC transfusions were received in the BL-ASCT group, the median PRBC requirements in the TS-ASCT group was 2 U (range, 0-12 U; P = .0001). Mean PRBC transfusion in TS-ASCT group were 3.21 [range, 0-12 transfusions]). The median platelet requirements for the BL-ASCT group vs TS-ASCT group was 0 U (range, 0-1 U) vs 1 U (range, 0-11 U), respectively (P = .008). The mean platelet requirement among TS-ASCT group was 1.49 U [range, 0-11 U). The transfusion requirements are outlined in Table 6 . One patient in the BL-ASCT group changed their mind regarding transfusion support and received 1 unit of platelets when their platelet count was <10,000/μL without any bleeding.
Complications
There was no transplant-related mortality in the either group. The most commonly anticipated problems with BL-ASCT (ie, hematologic and cardiac complications) were reported.
Hematologic complications
Any bleeding or thrombotic complications were considered as events. The complications were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events. No bleeding or thrombotic complications occurred in the BL-ASCT group, as summarized in Table 6 . There were 2 (3%) episodes of menstrual bleeding in the TS-ASCT group and no bleeding-associated mortality. Both of those grade 2 menstruation-related bleeding episodes resolved with the initiation of progesterone-based contraception and platelet support. One (1.5%) grade 3 thrombotic event (deep vein thrombosis) occurred in the TS-ASCT group. That patient received full anticoagulation throughout the peri-ASCT course and platelet support with an increased platelet threshold of 50,000/μL until platelet engraftment was achieved. No bleeding complications occurred in this patient.
Cardiac complications
At baseline, 62% of patients in the BL-ASCT group and 52% of those in the TS-ASCT group (P = .438) had at least 1 CV risk factor (arrhythmia, congestive heart failure, diabetes mellitus type-2, hypertension, or hyperlipidemia). No cardiac complications were observed in the BL-ASCT group. During the peri-ASCT period, there was 1 (1.5%) episode of grade 3 hypotension preceding sepsis during the neutropenic phase in the TS-ASCT group. That patient was resuscitated with timely initiation of fluids and antibiotics. One episode of atrial fibrillation (1.5%) was observed in the TS-ASCT group. Four patients (17%) in the BL-ASCT group and 2 (3%) in the TS-ASCT group (P = .017) had grade 2 hypertension.
PFS and OS
The management of both patient groups and their clinical outcomes after autologous transplantation were very similar. Sixty-three percent of patients in the BL-ASCT group and 61% of those in the TS-ASCT group received maintenance therapy (P = .926). The median PFS for the BL-ASCT and TS-ASCT groups was 36 months and 44 months, respectively. The difference in PFS between the 2 groups was not statistically significant, as illustrated in Figure 2 (P = .277). Survival did not differ between the groups, and the median OS has not been reached for either group at a median follow-up of 59 months (P = .627) as illustrated in Figure 1 .
DISCUSSION
The use of HDT-ASCT for the treatment of myeloma and other plasma cell dyscrasias (PCDs) has resulted in significant improvements in OS and PFS. Evidence from a recent phase 3 trial from the Intergroupe Francophone du Myelome group suggests that early ASCT results in higher rates of deeper responses, as determined by a negative assessment for minimal residual disease (sensitivity, For the BL-ASCT group, the median PFS was 36 months vs 44 months in the TS-ASCT group (P = .277). −6 ) and prolonged PFS.
2 HDT-ASCT has become an integral component of the myeloma armamentarium, as demonstrated by increasing volumes of ASCTs offered to patients with myeloma and those with other PCDs. 3 Although the receipt of ASCT has been extended to patients who once were not considered candidates (elderly patients, patients with comorbidities), to date, most transplant centers do not offer ASCT to patients who decline transfusion of blood products. 3 TRM for myeloma patients has significantly declined over the last decade. A European analysis that included 53,675 patients with myeloma who underwent ASCT from 31 European countries reported an all-cause, day-100 mortality rate below 2.4% for all age groups between 2006 and 2010. 4 A similar analysis by the Center for International Blood and Marrow Transplant Research analyzing 11,430 ASCTs in the United States between 2008 and 2011 reported a 1-year nonrelapse mortality rate below 2%. More important, the nonrelapse mortality rate among patients aged >70 years was 0%, substantiating the need for heightened pretransplantation safety evaluation and patient selection in this group of patients. 5 In this context, offering the benefit of ASCT to patients with myeloma who undergo BL-ASCT and, at the same time, offering the expectation of lowered TRM, similar to that achieved with TS-ASCT, comes as a challenge.
The safety of the BL-ASCT is supported by other studies. Ford and colleagues from the Center for Bloodless Medicine and Surgery at Pennsylvania Hospital reported on 125 JW patients who received BL-ASCT (lymphoma, n = 55; myeloma, n = 68; amyloidosis, n = 2). Two major and 15 minor bleeding complications were reported. Six patients (4.8%) died before day 30, and 10 (8%) who died before day 100 were considered TRMs. One-half of the deaths occurring before day 30 were cardiac, leading this group to involve cardiologists in pretransplantation evaluations and critical care, subsequently reducing the incidence of cardiac-related fatalities and TRM. 1 Nevertheless, relative to the TS-ASCT group, the BL-ASCT group had significantly higher TRM than was expected. This increase in TRM is not acceptable and necessitates further measures to ensure safety. 1 Our group has performed 1680 ASCTs for myeloma/PCDs during the last decade, including 24 BL-ASCTs. We report no TRM and no CV complications in this group of patients, in which the OS was comparable to that achieved by a matched cohort of patients who underwent TS-ASCT, suggesting that BL-ASCT should be offered to appropriate transplant-eligible candidates.
The median length of stay among BL-ASCT patients was 15 days (range, 12-24) compared with 16 days among TS-ASCT patients (range, 12-29 days). This differed from Ford and colleague's data, in which the median number of days of hospitalization for patients in the BL-ASCT group was 19 days (range, 5-35 days), which likely was a consequence of various diagnoses and conditioning regimens. Long-term PFS and OS did not differ between the BL-ASCT and TS-ASCT groups, demonstrating that carefully selected patients and the use of a specialized protocol can result in similar long-term outcomes for patients who undergo BL-ASCT. Furthermore, these outcomes were comparable to those reported in other studies that evaluated ASCT for patients with myeloma. The 0% TRM for both groups in our analyses supports the continued application of this approach to patients who prefer BL-ASCT. One possible explanation for the difference in TRM between our report and the original report by Ford et al 1 is our institutional BL-ASCT protocol (Table 3) , which is easily applicable and can assist in the standardization of care for all patients with myeloma who undergo BL-ASCT.
Although we have not performed a cost-effectiveness analysis between these groups, it seems reasonable to assume that, at the least, costs would be similar between the BL-ASCT and TS-ASCT groups, especially given the absence of transfusion-associated costs and because the length of stay, engraftment parameters, TRM, and cardiac complications are similar for the 2 groups.
From a CV standpoint, older patients who receive alkylating agents have a higher risk of complications. Careful evaluation of cardiac history and expected cardiac-related complications is crucial. At baseline, 4 patients (6%) in our TS-ASCT group had prior history of arrhythmia. Sixty-two percent of patients in the BL-ASCT group and 52% of those in the TS-ASCT group had at least 1 cardiac risk factor (arrhythmia, congestive heart failure, diabetes, hypertension, or hyperlipidemia). Although none of the patients in the BL-ASCT group had any CV complications, 1 patient (1.5%) in the TS-ASCT group (who had a history of atrial fibrillation) had an episode of atrial fibrillation. Although 42% of patients in the BL-ASCT group and 40% of those in the TS-ASCT group (P = .886) had a history of hypertension, a greater number of those in the BL-ASCT group experienced hypertension during the peri-ASCT course. Four patients (17%) in BL-ASCT group and 2 (3%) in the TS-ASCT group (P = .017) had grade 2 hypertension. Because of the decreased oral intake Cancer January 15, 2019 and potential for volume depletion during transplantation, withholding diuretics and other antihypertensive medications upon admission for ASCT and initiating adjusted doses during the peri-ASCT course as needed is a common practice and explains the increased rates of hypertension.
Finally, we observed no TRM in the BL-ASCT group, and the long-term outcomes in both groups were similar to those reported in other trials that evaluated ASCT in patients with myeloma. Go et al evaluated the association between the volume of patients with myeloma treated at a facility annually and all-cause mortality using the National Cancer Database. Among 94,722 patients with newly diagnosed myeloma who were treated at 1333 facilities between 2003 and 2011, in multivariate analysis, the authors were able to demonstrate that the facility volume was an independent risk factor for all-cause mortality. Receiving treatment for myeloma at a high-volume center is associated with lower mortality and increased survival. 6 In conclusion, our findings demonstrate BL-ASCT is feasible with specialized protocols aimed at minimizing blood loss. Although retrospective analyses have inherent limitations, and not all confounding variables can be accounted for, our results clearly demonstrate that BL-ASCT can be done safely; is associated with comparable TRM, CV, and hematologic complications; and can yield similar engraftment and survival parameters compared with TS-ASCT. We have a similar experience of feasibility and safety offering BL-ASCT to patients with lymphoma supporting a rationale for offering BL-ASCT to a broader population and conducting a prospective clinical trial of BL-ASCT vs TS-ASCT patients.
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